Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

Share Purchase Plan and Options Offer Open

Not for release to US wire services or distribution in the United States

16 November 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases announced on Monday, 2 November 2026 that it had received firm commitments to raise A$4.3 million (before costs) through the issue of 63.2 million new fully paid ordinary shares ("Shares") (the "New Shares") at A$0.068 per New Share ("Placement Offer Price") (the "Placement"). The Placement includes a A$150,000 commitment from the Company's Board and management (with Director participation subject to shareholder approval). The Company also announced that it will offer Eligible Shareholders the opportunity to participate in a Share Purchase Plan ("SPP") which targets to raise an additional A$2.0 million.

Participants in both the Placement and SPP will each be entitled to be made an offer, subject to shareholder approval, to apply to receive (for no consideration) one new option ("New Option") for each New Share issued under the Placement or subscribed for under the SPP (as applicable), exercisable at A$0.12 and expiring 18 months from issue. Subject to satisfying spread requirements set out in ASX Listing Rule 2.5, condition 6, the New Options are intended to be quoted on the ASX and the issue of New Options is subject to such quotation. The New Options will be offered to eligible participants via a prospectus lodged with the Australian Securities and Investments Commission ("ASIC") and to be released to ASX today.

Funds raised under the Placement and SPP, together with existing cash (following the redemption of all outstanding convertible notes then held by Obsidian Global GP, LLC) and anticipated R&D tax incentive refunds, will be applied to:

- Clinical and pre-clinical activities, including completion of Regimen I of the Phase 2/3 HEALEY ALS Platform Trial, with topline results anticipated in late Q2 CY2027;
- Manufacturing, supply-chain readiness and regulatory activities to support the continued clinical development and preparation for potential commercialisation of NUZ-001;
- Market engagement and business development activities, including potential strategic partnering opportunities; and
- Corporate costs (commercial, finance and governance), working capital and transaction expenses.

The SPP will open at 9.00am (Melbourne time) today, Monday, 16 November 2026, to "Eligible Shareholders", being persons who were registered holders of Shares in Neurizon at 7.00pm Friday, 30 October 2026, with a registered address in Australia or New Zealand at that time as shown on the share register, who are not in the United States and are not acting for the account or benefit of a person in the United States (and who meet certain other eligibility criteria), to apply for up to A$30,000 worth of New Shares at an issue price of A$0.068 per New Share (i.e. the same price as the Placement Offer Price) ("SPP Offer"). New Shares issued in the Placement are not eligible to participate in the SPP.

The SPP is being offered to Eligible Shareholders to extend an opportunity to invest on the same terms as the institutional and sophisticated investors who participated in the Placement. The SPP will enable Eligible Shareholders, irrespective of the size of their holding, to apply to participate in the capital raising at the same price as the Placement Offer Price, and not incur any brokerage or transaction costs. Participation in the SPP is optional.

Chief Executive Officer, Dr Chris Bremer, said: "*We are pleased to offer our existing shareholders the opportunity to participate in this capital raising on the same terms as the investors in the Placement, at the same price, with no brokerage, and being entitled to be made an offer, subject to shareholder approval, to apply to receive (for no consideration) one New Option for each share subscribed for under the SPP.*

Our shareholders have supported Neurizon through an important period. With the Phase 2/3 HEALEY ALS Platform Trial fully recruited, topline results anticipated in late Q2 CY2027, and no convertible notes on issue, the SPP gives them the opportunity to participate as we approach this key milestone. Strong participation in the SPP would also strengthen our funding position and may reduce the need to draw further on the Obsidian facility."

The SPP is targeting to raise A$2 million. Neurizon may (in its absolute discretion) in a situation where total demand exceeds A$2 million, decide to increase the amount to be raised under the SPP to reduce or eliminate the need for scale back. Neurizon reserves the right to scale back applications at its absolute discretion.

The SPP is not underwritten.

New Shares issued under the SPP will rank equally with existing fully paid ordinary shares then on issue.

As stated above, participants under the SPP will be entitled to be made a separate offer by the Company, subject to shareholder approval, to apply to receive (for no consideration) 1 New Option for every 1 New Share subscribed for under the SPP (rounded down to the nearest whole number) on the same terms as participants under the Placement ("SPP Options Offer").

SPP booklet and prospectus

The SPP is subject to the terms and conditions set out in the SPP booklet (a copy of which is attached). The New Options will be offered to Eligible Shareholders via a prospectus lodged with ASIC and to be released to ASX today. Eligible Shareholders who have provided an email address will be sent an email communication with details of how to obtain a copy of the SPP booklet, prospectus and their personalised application form (a sample of which is attached). Eligible Shareholders who have not provided an email address will be sent an SPP and New Options offer letter (a sample of which is attached) via post with details of how to obtain a copy of the SPP booklet, prospectus and their personalised application form. The SPP booklet, prospectus and personalised application forms are also available at: https://portal.automic.com.au/investor/home.

Eligible Shareholders are encouraged to read the SPP booklet and prospectus carefully, and if in any doubt about whether or not to accept the SPP Offer and SPP Options Offer, to consult with a financial or other professional adviser.

The SPP Offer and SPP Options Offer are each expected to close at **5.00pm (Melbourne time) on Friday, 4 December 2026** (unless extended, withdrawn or closed early by the Company). To apply for New Shares under the SPP, Eligible Shareholders must, by 5.00pm (Melbourne time) on Friday, 4 December 2026, make a payment directly via BPAY® or electronic funds transfer in accordance with the instructions on their personalised application form. The SPP Options Offer application form will be part of the application form for participation in the SPP Offer. SPP participants are not required to separately return the SPP Options Offer application form. By applying for New Shares in accordance with the SPP Offer (including by paying the application monies for New Shares in accordance with the instructions on that application form) SPP participants will also be applying for New Options under the SPP Options Offer on the terms of the SPP Options Offer application form and the prospectus.

Shareholders with questions in relation to how to participate in the SPP Offer and SPP Options Offer should contact Neurizon's share registry, Automic, from 8.30am to 7.00pm (Melbourne time) Monday to Friday (excluding public holidays) on 1300 288 664 (for callers within Australia) or +61 2 9698 5414 (for callers outside Australia) or email corporate.actions@automicgroup.com.au during the offer period or consult their financial or other professional adviser.

INDICATIVE OFFER TIMETABLE[1]	
Event	**Dates (Melbourne time)**
SPP record date	7.00pm, Friday, 30 October 2026
SPP opening date and New Options offer opening date	9.00am, Monday, 16 November 2026
SPP Offer and SPP Options Offer closing date	5.00pm, Friday, 4 December 2026
Results of SPP announced	Friday, 11 December 2026
Issue of New Shares under SPP	Friday, 11 December 2026
New Shares under SPP commence trading on ASX	Monday, 14 December 2026
Despatch of holding statements in respect of SPP New Shares	Tuesday, 15 December 2026
General Meeting to approve Director participation and the New Options	Thursday, 17 December 2026
Issue of New Shares under Director participation[2]	Monday, 21 December 2026
Placement options offer closing date	5.00pm, Monday, 21 December 2026
Expected normal trading of New Shares under Director Participation and issue of New Options under Placement and SPP[2]	Tuesday, 22 December 2026
Expected commencement of normal trading of New Options on ASX[2]	Wednesday, 23 December 2026

1. The above timetable is indicative only. The Company reserves the right to close the SPP early, extend the SPP closing date or to withdraw the SPP, in its sole and absolute discretion, by lodging an announcement with the ASX. The closing date of the SPP Options Offer is the same closing date as the SPP Offer. Any change to the closing date of the SPP will also change the closing date of the SPP Options Offer. The commencement of trading and quotation of New Shares and New Options is subject to ASX confirmation. The Company gives no assurance that such quotation will be granted.

2. Subject to shareholder approval being obtained at the General Meeting and quotation condition being satisfied (as applicable).

-ENDS-

This announcement has been authorised for release by the Board of Neurizon Therapeutics Limited.

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or in any other jurisdiction in which such offer or solicitation would be unlawful. The securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "US Securities Act"), or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States except in a transaction exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

For further information, please contact:

Marketing & Corporate Affairs
Lidija Damjanovic
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504

Investor Relations
Henry Jordan
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a late clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical program, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit
https://investorhub.neurizon.com

Neurizon® is a registered trademark of Neurizon Therapeutics Limited

Neurizon Therapeutics Limited
Share Purchase Plan Booklet

This is an important document and requires your immediate attention. You should read this Booklet in full.

Eligible Shareholders have the opportunity to participate in the Share Purchase Plan offer by applying for up to $30,000 worth of new Shares without incurring brokerage or other transaction costs. Details of the offer and how to participate are set out in this Booklet.

Participants under the SPP will be entitled to be made a separate offer by the Company, subject to Shareholder approval at the General Meeting, to apply to receive (for no consideration) 1 new Option for every 1 SPP Share subscribed for under the SPP (rounded down to the nearest whole number). Subject to satisfying spread requirements set out in Listing Rule 2.5, condition 6, the new Options are intended to be quoted on the ASX and the issue of new Options is subject to such quotation. The new Options are not offered under this Booklet. The new Options will be offered under a separate prospectus.

Applications for SPP Shares under the SPP Offer must be received by 5.00pm (Melbourne time) on Friday, 4 December 2026.

This Booklet is dated 16 November 2026.

Table of contents

1 Letter to Shareholders 1

2 Summary of important dates 4

3 Summary of SPP 5

4 SPP Terms and Conditions 10

4.1 Offer 10
4.2 Eligible Shareholders 11
4.3 Joint holders and Custodians 11
4.4 Applications for SPP Shares 12
4.5 Issue Price 13
4.6 Number of SPP Shares to be issued 14
4.7 Issue of SPP Shares 14
4.8 Shareholders outside Australia 14
4.9 Representations, warranties and acknowledgements 14
4.10 Scale back 18
4.11 Dispute resolution 18
4.12 Variation and termination 18
4.13 Privacy policy 19
4.14 ASIC Corporations Instrument compliance 19
4.15 Underwriting 19
4.16 Governing law 19

5 Glossary 20

Important information

This Booklet is intended for use only in connection with the SPP Offer to Eligible Shareholders. This Booklet does not constitute an offer of securities in any place outside Australia or New Zealand and no action has been taken to permit an offering of Shares in any jurisdiction outside of Australia and New Zealand. The distribution of this Booklet is restricted by law and persons (including Custodians) who come into possession of this document should observe any such restrictions. Due to legal restrictions, Custodians may not distribute this Booklet or any other document relating to the SPP, and may not permit any beneficial Shareholder to participate in the SPP, in any country outside Australia or New Zealand.

This Booklet may not be distributed or released in the United States (**U.S.**). This Booklet does not constitute an offer to sell, or a solicitation of an offer to buy, any Shares in the U.S. or in any jurisdiction in which such an offer would be illegal. The Shares to be offered and sold under the SPP Offer have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (**Securities Act**), or the securities laws of any U.S. state or other jurisdiction of the U.S., and may not be offered or sold, directly or indirectly, to persons in the U.S. or to any person acting for the account or benefit of a person in the U.S. (to the extent such person is acting for the account or benefit of a person in the U.S.) except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws.

Participants under the SPP will be entitled to be made a separate offer by the Company, subject to Shareholder approval at the General Meeting, to apply to receive (for no

consideration) 1 new Option for every 1 SPP Share subscribed for under the SPP (rounded down to the nearest whole number). Subject to satisfying spread requirements set out in Listing Rule 2.5, condition 6, the new Options are intended to be quoted on the ASX and the issue of new Options is subject to such quotation. The new Options are not offered under this Booklet. The new Options will be offered to eligible participants via a prospectus expected to be lodged with ASIC and released to ASX on or around Monday, 16 November 2026.

The SPP Offer is not a recommendation to acquire Shares. This document does not constitute financial product advice and does not take into account the individual investment objectives, financial situation or particular needs of each Eligible Shareholder. Eligible Shareholders wanting to participate in the SPP should obtain independent advice in relation to the taxation and other consequences of an investment under the SPP before making a decision as to whether to participate in the SPP. A cooling-off regime does not apply in relation to the acquisition of Shares under the SPP.

This Booklet does not purport to include or summarise all information that an investor should consider when making an investment decision, nor does it contain all information which would be required in a prospectus, product disclosure statement or other disclosure document prepared in accordance with the Corporations Act or any other applicable law. This Booklet should be read in conjunction with Neurizon's periodic and continuous disclosure announcements lodged with the ASX which are available at www.asx.com.au.

1 Letter to Shareholders

Dear Shareholder

On behalf of the directors of Neurizon Therapeutics Limited (**Neurizon** or the **Company**), I am pleased to offer you the opportunity to participate in the Neurizon Share Purchase Plan (**SPP**), which allows Eligible Shareholders to subscribe for up to $30,000 worth of new Shares in Neurizon (**SPP Shares**) without incurring brokerage or other transaction costs.

The SPP aims to raise $2 million and is not underwritten.

Neurizon reserves the right to determine the aggregate amount it raises through the SPP. If total demand exceeds $2 million, Neurizon may decide to increase the amount to be raised under the SPP to reduce or eliminate the need for scale back. Neurizon may, in its absolute discretion, scale back the number of SPP Shares that will be issued to individual Eligible Shareholders under the SPP Offer to the extent, and in the manner, it sees fit.

The SPP follows Neurizon's successful placement, announced on Monday, 2 November 2026, which raised $4.3 million (before costs) (**Placement**), including participation by Directors of $100,000 in aggregate, subject to Shareholder approval at a general meeting expected to be held on or around Thursday, 17 December 2026 (**General Meeting**).

The SPP Shares are being offered at the Issue Price of $0.068 per SPP Share, being the same offer price as that under the Placement.[1]

For completeness, participants under the Placement will be entitled to be made an offer by the Company, subject to Shareholder approval at the General Meeting, to apply to receive (for no consideration) 1 new Option for every 1 new Share issued under the Placement (rounded down to the nearest whole number). Subject to satisfying spread requirements set out in Listing Rule 2.5, condition 6, the new Options are intended to be quoted on the ASX and the issue of new Options is subject to such quotation. The new Options will be offered to eligible participants via a prospectus expected to be lodged with ASIC and released to ASX on or around Monday, 16 November 2026.

In addition, participants under the SPP will be entitled to be made a separate offer by the Company, subject to Shareholder approval at the General Meeting, to apply to receive (for no consideration) 1 new Option for every 1 SPP Share subscribed for under the SPP (rounded down to the nearest whole number). Subject to satisfying spread requirements set out in Listing Rule 2.5, condition 6, the new Options are intended to be quoted on the ASX and the issue of new Options is subject to such quotation. The new Options are not offered under this Booklet. The new Options will be offered to eligible participants via a prospectus expected to be lodged with ASIC and released to ASX on or around Monday, 16 November 2026.

Use of proceeds

Funds raised under the Placement and SPP, together with existing cash (following the redemption of all outstanding convertible notes then held by Obsidian Global GP, LLC) and anticipated R&D tax incentive refunds, will be applied to:

- clinical and pre-clinical activities, including completion of Regimen I of the Phase 2/3 HEALEY ALS Platform Trial, with topline results anticipated in late Q2 CY2027;

[1] Represents:

- a 20.9% discount to the closing price of Shares traded on 28 October 2026 being the last trading day prior to the Company entering a two day trading halt to conduct the Placement;
- an 18.9% discount to the 5-day VWAP up to and including 28 October 2026 being the last trading day prior to the Company entering a two day trading halt to conduct the Placement (excluding 28 October 2026 as no sales in Shares were recorded on that day); and
- a 19.3% premium to the closing price of $0.057 as at 12 November 2026.

- manufacturing, supply-chain readiness and regulatory activities to support the continued clinical development and preparation for potential commercialisation of NUZ-001;
- market engagement and business development activities, including potential strategic partnering opportunities; and
- corporate costs (commercial, finance and governance), working capital and transaction expenses.

Further details about the Placement and the SPP, including a summary of some of the key risks associated with holding an investment in Neurizon, are included in Neurizon's ASX announcement released on Monday, 2 November 2026, which we encourage you to read. You can view this ASX announcement at www.asx.com.au (**ASX: NUZ**) and Neurizon's website: https://investorhub.neurizon.com/announcements.

Participation in the SPP

Participation in the SPP is voluntary and open to all Eligible Shareholders, being persons who were registered holders of Shares in Neurizon at 7.00pm (Melbourne time) on Friday, 30 October 2026 (**Record Date**), with a registered address in either Australia or New Zealand at that time as shown on the Register (and who meet certain other eligibility criteria). The SPP Offer is also being extended to Eligible Shareholders who are Custodians to participate in the SPP on behalf of certain Eligible Beneficiaries on the Terms and Conditions set out in this Booklet.

Persons in the United States are not eligible to participate in the SPP. Similarly, persons (including Custodians) who hold Shares on behalf of persons who reside outside Australia or New Zealand (including the United States) or are acting for the account or benefit of persons in the United States, are not eligible to participate in the SPP on behalf of those persons.

Once issued, SPP Shares will rank equally with existing Shares in Neurizon.

The terms and conditions of the SPP are provided in this Booklet. We urge you to read these materials in their entirety and seek your own financial and taxation advice in relation to the SPP, before you decide whether to participate.

How to apply for SPP Shares

To apply for SPP Shares, please follow the instructions in your personalised Application Form. Your personalised Application Form can be accessed via https://portal.automic.com.au/investor/home. In accordance with the instruction in your personalised Application Form, you must either:

- **make a payment directly via BPAY®**[2], which is the fastest and easiest way to apply. For completeness, you can only make payment via BPAY if you are the holder of an account with an Australian branch of a financial institution that supports BPAY transactions; or
- pay for SPP Shares by making an electronic funds transfer (**EFT**).

Cheque, bank draft, money order and cash payments will not be accepted.

Eligible Shareholders wishing to apply for SPP Shares must ensure that their payment is received by no later than **5.00pm (Melbourne time) on Friday, 4 December 2026**.

[2] Registered by BPAY Pty Ltd (ABN 69 079 137 518).


Questions and further information

This Booklet contains important information about the SPP to assist you in deciding whether to participate in the SPP. You should read this Booklet carefully and in its entirety before deciding whether to apply.

If you have any questions in relation to how to participate in the SPP, please contact the Registry from 8.30am to 7.00pm (Melbourne time) Monday to Friday (excluding public holidays) on 1300 288 664 (for callers within Australia) or +61 2 9698 5414 (for callers outside Australia) or email corporate.actions@automicgroup.com.au during the Offer Period, or consult your financial or other professional adviser. If you have any questions in relation to whether an investment in Neurizon through the SPP Offer is appropriate for you, please contact your stockbroker, accountant or other professional adviser.

Thank you for your continued support of Neurizon.

Yours sincerely



Sergio Duchini
Chair
Neurizon Therapeutics Limited

2 Summary of important dates

Event	Date
Record Date (the date that eligibility to participate in the SPP was determined)	7.00pm (Melbourne time), Friday, 30 October 2026
Opening Date for applications	9.00am (Melbourne time), Monday, 16 November 2026
Closing Date for applications	5.00pm (Melbourne time), Friday, 4 December 2026
Results of SPP announced	Friday, 11 December 2026
Issue of SPP Shares	Friday, 11 December 2026
SPP Shares commence trading on ASX	Monday, 14 December 2026
Despatch of holding statements	Tuesday, 15 December 2026
General Meeting	Thursday, 17 December 2026

This timetable is indicative only and subject to change. Neurizon reserves the right to alter the dates above at its discretion, subject to the Listing Rules and Corporations Act. All references to times in this Booklet are to Melbourne time.

3 Summary of SPP

You should read this section in conjunction with the Terms and Conditions set out in section 4 of this Booklet.

Key SPP details	Summary
SPP Offer	Eligible Shareholders of Neurizon may subscribe for up to $30,000 worth of SPP Shares without brokerage or other transaction costs.
Purpose of the SPP	Funds raised under the Placement and SPP, together with existing cash (following the redemption of all outstanding convertible notes then held by Obsidian Global GP, LLC) and anticipated R&D tax incentive refunds, will be applied to: • clinical and pre-clinical activities, including completion of Regimen I of the Phase 2/3 HEALEY ALS Platform Trial, with topline results anticipated in late Q2 CY2027; • manufacturing, supply-chain readiness and regulatory activities to support the continued clinical development and preparation for potential commercialisation of NUZ-001; • market engagement and business development activities, including potential strategic partnering opportunities; and • corporate costs (commercial, finance and governance), working capital and transaction expenses. For further information, refer to the Company's ASX announcement dated 2 November 2026.
Voluntary participation	Participation in the SPP is entirely voluntary. Before you decide whether to participate in the SPP, Neurizon recommends you seek independent financial advice from your stockbroker, accountant or other professional adviser. If you do not wish to participate in the SPP, no further action is required on your part.
Issue Price of the SPP Shares	The Issue Price of the SPP Shares is $0.068 per SPP Share, being the same offer price as that under the Placement.[3]

[3] Represents:

- a 20.9% discount to the closing price of Shares traded on 28 October 2026 being the last trading day prior to the Company entering a two day trading halt to conduct the Placement;
- an 18.9% discount to the 5-day VWAP up to and including 28 October 2026 being the last trading day prior to the Company entering a two day trading halt to conduct the Placement (excluding 28 October 2026 as no sales in Shares were recorded on that day); and
- a 19.3% premium to the closing price of $0.057 as at 12 November 2026.

Key SPP details	Summary
	There is a risk that the market price of Shares may rise or fall between the date of this Booklet and the time of issue of SPP Shares under the SPP Offer. This means that the price you pay for the SPP Shares issued to you may be less than or more than the market price of Shares at the date of this Booklet or the time of issue. Your application is unconditional and may not be withdrawn even if the market price of Shares is less than the Issue Price.
Eligible Shareholders	Eligible Shareholders are eligible to participate in the SPP, being persons who were registered holders of Shares at 7.00pm (Melbourne time) on Friday, 30 October 2026 with a registered address in either Australia or New Zealand at that time as shown on the Register, provided that such holders are not in the United States and are not acting for the account or benefit of a person in the United States or, in the event that such holders are acting for the account or benefit of a person in the United States, such holders are not participating in the SPP in respect of that person. The SPP Offer is also being extended to Eligible Shareholders who are Custodians to participate in the SPP on behalf of Eligible Beneficiaries on the Terms and Conditions provided in this Booklet. Custodians may only distribute documents relating to the SPP to Eligible Beneficiaries. In particular, due to legal restrictions, Custodians may not distribute this Booklet or any other document relating to the SPP, and may not permit any beneficial Shareholder to participate in the SPP, in any country outside Australia or New Zealand.
Non-renounceable and non-transferable	The SPP Offer is non-renounceable and cannot be transferred.
Investment amount	Eligible Shareholders may apply for SPP Shares in parcels valued at $1,000, $2,500, $5,000, $7,500, $10,000, $12,500, $15,000, $20,000, $25,000 or $30,000. The number of SPP Shares issued to an Eligible Shareholder will be rounded up to the nearest whole number after dividing the application monies by the Issue Price. Neurizon may (in its absolute discretion) decide to: • increase the amount to be raised under the SPP to reduce or eliminate the need for scale back; and/or • undertake a scale back of applications (in whole or in part) to the extent, and in the manner, it sees fit.
How to apply	Eligible Shareholders wishing to apply for SPP Shares may do so by making payment via: • BPAY; or • EFT.

Key SPP details	Summary
	Instructions about how to apply for SPP Shares and make payment (including your unique reference numbers) are contained in your personalised Application Form which can be accessed via https://portal.automic.com.au/investor/home. You will need to provide your securityholder reference number (**SRN**) or holder identification number (**HIN**) and follow the instructions provided. Your SRN or HIN can be found on your holding statement and other securityholder communications. You can request a paper copy of this Booklet and your personalised Application Form by contacting the Registry from 8.30am to 7.00pm (Melbourne time) Monday to Friday (excluding public holidays) on 1300 288 664 (for callers within Australia) or +61 2 9698 5414 (for callers outside Australia) during the Offer Period. To accept the SPP Offer using these paper copy documents, you will still need to make payment via BPAY or EFT. You can only make payment via BPAY if you are the holder of an account with an Australian branch of a financial institution that supports BPAY transactions. There is no need to return your personalised Application Form but you will be taken to have made the statements and certifications that are set out in the Application Form[4]. Payment for SPP Shares for the appropriate amount must be received by the Registry prior to the close of the SPP Offer at **5.00pm (Melbourne time) on Friday, 4 December 2026**. You should be aware that your financial institution may implement earlier cut-off times with regard to electronic payment and you should therefore take this into consideration when making payment. Neurizon and the Registry accept no responsibility for any delay in the receipt of payment. Cheque, bank draft, money order and cash payments will not be accepted. If you have any questions in relation to how to participate in the SPP, please contact the Registry from 8.30am to 7.00pm (Melbourne time) Monday to Friday (excluding public holidays) on 1300 288 664 (for callers within Australia) or +61 2 9698 5414 (for callers outside Australia) or email corporate.actions@automicgroup.com.au during the Offer Period or consult your financial or other professional adviser. If you have any questions in relation to whether an investment in Neurizon through the SPP Offer is appropriate for you, please contact your stockbroker, accountant or other professional adviser.
Rights attached to SPP Shares	SPP Shares will rank equally with all other Shares on issue from their date of issue.

[4] **Important Not**e: By submitting your payment for SPP Shares you certify and represent to Neurizon that the aggregate application money paid by you in any capacity (except as Custodian) for the SPP Shares under your application and any other Shares issued to you, or a Custodian on your behalf and at your instruction, under the SPP or any other similar arrangement operated by Neurizon in the 12 months before the date of your application, is not more than $30,000.

Key SPP details	Summary
Custodians	The SPP Offer is being extended to Eligible Shareholders who are Custodians and who wish to apply for SPP Shares on behalf of Eligible Beneficiaries. The SPP Offer is being offered to Custodians as the registered Shareholder. Custodians are not required to participate on behalf of their Eligible Beneficiaries. Custodians may choose whether or not to extend the SPP Offer to their Eligible Beneficiaries. Notwithstanding the foregoing, Custodians may not participate in the SPP on behalf of, and may not distribute this Booklet or any documents relating to this SPP to, any person in the United States. In the event that a Custodian is acting for the account or benefit of a person in the United States, it is not permitted to participate in respect of that person. If you wish to apply as a Custodian under the SPP Offer to receive SPP Shares for one or more Eligible Beneficiaries, you must complete and submit a Custodian Certificate that contains further certifications and details before your application will be accepted. Applications by Custodians that are not accompanied by a duly completed Custodian Certificate will be rejected. By applying as a Custodian on behalf of Eligible Beneficiaries to purchase SPP Shares, you certify (amongst other things) that each Eligible Beneficiary has not exceeded the $30,000 limit. To request a Custodian Certificate or for further information about the Custodian application process, please contact the Registry from 8.30am to 7.00pm (Melbourne time) Monday to Friday (excluding public holidays) on 1300 288 664 (for callers within Australia) or +61 2 9698 5414 (for callers outside Australia) or email corporate.actions@automicgroup.com.au. A Custodian will be ineligible to participate in the SPP if their participation would be in breach of *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547*.
Issue of SPP Shares	Holding statements are expected to be despatched on or around Tuesday, 15 December 2026.
Oversubscriptions	The amount that each Eligible Shareholder can apply for under the SPP Offer is capped at $30,000. The SPP aims to raise up to approximately $2 million. Neurizon may decide to accept applications (in whole or in part) that result in the SPP raising more or less than this amount in its absolute discretion. Neurizon may, in its absolute discretion, scale back the number of SPP Shares that will be issued to individual Eligible Shareholders under the SPP Offer. If this happens you may be issued SPP Shares to a value that is less than the value of SPP Shares you applied for and the difference will be refunded to you (without interest) (except that any excess amount of $5.00 or less will be retained by Neurizon and not refunded).

Key SPP details	Summary
Refunds	If you are entitled to a refund of all or any of your application monies, the refund will be paid to you in Australian currency, without interest, as soon as practicable by direct credit to your nominated bank account (as recorded with the Registry). Please note that you can update your bank details at https://portal.automic.com.au/investor/home. By applying for SPP Shares, each Eligible Shareholder authorises Neurizon to pay any monies to be refunded to the Eligible Shareholder's nominated bank account (as recorded with the Registry).
Option offer entitlement	Participants under the SPP will be entitled to be made a separate offer by the Company, subject to Shareholder approval at the General Meeting, to apply to receive (for no consideration) 1 new Option for every 1 SPP Share subscribed for under the SPP (rounded down to the nearest whole number). Subject to satisfying spread requirements set out in Listing Rule 2.5, condition 6, the new Options are intended to be quoted on the ASX and the issue of new Options is subject to such quotation. The new Options are not offered under this Booklet. The new Options will be offered to eligible participants via a prospectus expected to be lodged with ASIC and released to ASX on or around Monday, 16 November 2026. Each new Option will have an exercise price of $0.12 and an expiry date of eighteen (18) months from the date of issue, and will otherwise be on the terms set out in the prospectus. New Options will not be issued unless and until Shareholder approval is obtained at the General Meeting and the quotation condition is satisfied. If Shareholder approval for the issue of new Options is not obtained at the General Meeting and/or the quotation condition is not satisfied, no new Options will be issued. This will not affect the issue of SPP Shares and no application monies will be refunded on that basis.
More information	If you have any questions in relation to how to participate in the SPP, please contact the Registry from 8.30am to 7.00pm (Melbourne time) Monday to Friday (excluding public holidays) on 1300 288 664 (for callers within Australia) or +61 2 9698 5414 (for callers outside Australia) or email corporate.actions@automicgroup.com.au during the Offer Period or consult your financial or other professional adviser. If you have any questions in relation to whether an investment in Neurizon through the SPP Offer is appropriate for you, please contact your stockbroker, accountant or other professional adviser.

4 SPP Terms and Conditions

Important notice and disclaimer

This Booklet does not provide financial advice and has been prepared without taking account of any person's investment objectives, financial situation or particular needs. You should consider the appropriateness of participating in the SPP having regard to your investment objectives, financial situation or particular needs. Shareholders should seek independent financial and taxation advice before making any investment decision in relation to these matters.

The offer of SPP Shares under the SPP is made in accordance with *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547*, which grants relief from the requirement for Neurizon to provide prospectus disclosure in relation to the SPP. This Booklet does not constitute a prospectus or product disclosure statement, and has not been lodged with ASIC or any other regulator. The issue of a prospectus or product disclosure statement is not required for the purpose of the SPP Offer. You must rely on your own knowledge of Neurizon, previous disclosure made by Neurizon to ASX and if necessary, consult with your professional adviser when deciding whether or not to participate in the SPP.

If you participate in the SPP by making a payment, you are accepting the risk that the market price of Shares may change between the Record Date, the date on which a payment is received and the Issue Date. This means that, up to and/or after the Issue Date, you may be able to buy Shares on ASX at a lower price than the Issue Price.

Please read these Terms and Conditions carefully, as you will be bound by them in participating in the SPP. Shareholders accepting the SPP Offer will also be bound by the constitution of Neurizon.

The other sections of this Booklet (including the Glossary) and the Application Form form part of these Terms and Conditions.

4.1 Offer

(a) Neurizon offers each Eligible Shareholder the opportunity to purchase up to $30,000 worth of SPP Shares under the SPP subject to and in accordance with the Terms and Conditions (**SPP Offer**).

(b) The SPP Offer opens at 9.00am (Melbourne time) on Monday, 16 November 2026 and closes at 5.00pm (Melbourne time) on Friday, 4 December 2026 (or such other date as Neurizon determines, in its absolute discretion).

(c) Participation in the SPP is voluntary. If you choose not to participate in the SPP, your right to participate lapses at the Closing Date, being 5.00pm (Melbourne time) on Friday, 4 December 2026 (or such other date as Neurizon determines, in its absolute discretion).

(d) The SPP Offer is non-renounceable and non-transferable and, therefore, Eligible Shareholders cannot transfer their right to purchase SPP Shares to a third party.

(e) The SPP Offer to each Eligible Shareholder (whether as a Custodian or on its own account) is made on the same terms and conditions, irrespective of the number of Shares they hold on the Record Date.

(f) All references to $ or dollars in this Booklet are references to Australian dollars unless otherwise indicated.

(g) Participants under the SPP will be entitled to be made a separate offer by the Company, subject to Shareholder approval at the General Meeting, to apply to

receive (for no consideration) 1 new Option for every 1 SPP Share subscribed for under the SPP (rounded down to the nearest whole number). Subject to satisfying spread requirements set out in Listing Rule 2.5, condition 6, the new Options are intended to be quoted on the ASX and the issue of new Options is subject to such quotation.

(h) The new Options are not offered under this Booklet. The new Options will be offered to eligible participants via a prospectus expected to be lodged with ASIC and released to ASX on or around Monday, 16 November 2026.

(i) Each new Option will have an exercise price of $0.12 and an expiry date of eighteen (18) months from the date of issue, and will otherwise be on the terms set out in the prospectus.

(j) New Options will not be issued unless and until Shareholder approval is obtained at the General Meeting and the quotation condition is satisfied. If Shareholder approval for the issue of new Options is not obtained at the General Meeting and/or the quotation condition is not satisfied, no new Options will be issued. This will not affect the issue of SPP Shares and no application monies will be refunded on that basis.

4.2 Eligible Shareholders

(a) You are eligible to participate in the SPP if you:

(1) were registered on the Register as a Shareholder at 7.00pm (Melbourne time) on Friday, 30 October 2026 (the **Record Date**);

(2) had a registered address in either Australia or New Zealand at that time as shown on the Register; and

(3) are not in the United States and are not acting for the account or benefit of a person in the United States or, in the event that you are acting for the account or benefit of a person in the United States, you are not participating in the SPP in respect of that person.

(b) The SPP Offer is also extended to Eligible Shareholders who are Custodians in accordance with sections 4.3(b) and 4.4(f) of the Terms and Conditions below.

(c) The Shares to be offered and sold under the SPP Offer have not been, and will not be, registered under the Securities Act, or the securities laws of any state or other jurisdiction of the United States. Accordingly, persons in the United States are not eligible to participate in the SPP. Similarly, persons who hold Shares on behalf of persons in the United States, or are acting for the account or benefit of persons in the United States, are not eligible to participate in the SPP on behalf of those persons. Shares to be offered and sold under the SPP Offer are subject to restrictions under Regulation S under the Securities Act.

4.3 Joint holders and Custodians

(a) If two or more persons are registered on the Register as jointly holding Shares, they are taken to be a single registered holder of Shares for the purposes of determining whether they are an Eligible Shareholder and a certification given by any of them is taken to be a certification given by all of them.

(b) Subject to these Terms and Conditions, Eligible Shareholders who are Custodians may participate in the SPP on behalf of each Eligible Beneficiary on whose behalf the Custodian is holding Shares. Due to legal restrictions, Custodians may not distribute this Booklet or any other document relating to the SPP to any person in, and may not participate in the SPP on behalf of, any

person in the United States. In the event that a Custodian is acting for the account or benefit of a person in the United States, it is not permitted to participate in respect of that person.

(c) If you hold Shares as a trustee or nominee for another person, but are not a Custodian, you cannot participate for beneficiaries in the manner described above. In this case, the rules for multiple single holdings apply and you may only contribute a maximum of $30,000 in applying for SPP Shares. You are not eligible to participate on behalf of a person who resides outside of Australia or New Zealand.

4.4 Applications for SPP Shares

(a) Eligible Shareholders may apply for SPP Shares in parcels valued at $1,000, $2,500, $5,000, $7,500, $10,000, $12,500, $15,000, $20,000, $25,000 or $30,000.

(b) Subject to section 4.4(c) of the Terms and Conditions below, no brokerage or other transaction costs will apply to the acquisition of SPP Shares.

(c) In the event of a change in legislation or regulation so that, at the date of any issue of Shares, stamp duty or any other tax or duty is payable in respect thereof, the amount of such stamp duty or other tax or duty shall be paid by the Eligible Shareholder to whom the Shares are issued and, in respect of each such Share, included in the calculation of the Issue Price.

(d) Eligible Shareholders who wish to apply for SPP Shares must follow the instructions set out in the 'How to apply' section of section 3 of this Booklet (see pages 6 and 7).

(e) Eligible Shareholders who receive more than one offer under the SPP (for example, because they hold Shares in more than one capacity or in different registered holdings) may apply on different Application Forms for SPP Shares but may not apply for SPP Shares with an aggregate value of more than $30,000.

(f) If you wish to subscribe for SPP Shares as a Custodian for one or more Eligible Beneficiaries, you must also complete and submit an additional Custodian Certificate that contains further certifications and details that complies with section 8(3) of *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547* before your application will be accepted. Applications by Custodians that are not accompanied by a duly completed Custodian Certificate will be rejected. To request a Custodian Certificate or for further information about the Custodian application process, please contact the Registry from 8.30am to 7.00pm (Melbourne time) Monday to Friday (excluding public holidays) on 1300 288 664 (for callers within Australia) or +61 2 9698 5414 (for callers outside Australia) or email corporate.actions@automicgroup.com.au.

(g) Neurizon may accept or reject your application for SPP Shares in whole or in part in its absolute discretion including, without limitation, if:

(1) your application does not comply with these Terms and Conditions;

(2) it appears you are not an Eligible Shareholder (subject to compliance with any applicable ASIC or ASX requirements);

(3) your application might prejudice the effective operation of the SPP or give rise to a breach of any applicable law or regulation (including *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547* or any other ASIC instrument);

(4) your name is not recorded in the Register on the Record Date. For example, applications by people claiming an interest in Shares through a registered holder of Shares will not be accepted;

(5) your payment is not received by the Closing Date;

(6) it appears that you are applying to purchase more than $30,000 of SPP Shares in aggregate (including as a result of Shares you hold directly, jointly or through a Custodian or nominee arrangement) or your application is not for an amount of $1,000, $2,500, $5,000, $7,500, $10,000, $12,500, $15,000, $20,000, $25,000 or $30,000;

(7) payment of the application monies is not submitted in Australian currency; or

(8) the amount of your payment is not equal to a valid parcel. If this occurs, Neurizon will:

(A) refund in full your application monies (without interest) and not issue any SPP Shares to you (except that any excess amount of $5.00 or less will be retained by Neurizon and not refunded); or

(B) issue to you the number of SPP Shares that would have been issued had you applied for the highest designated amount that is less than the amount of your payment and refund to you the excess of your application monies (without interest) (except that any excess amount of $5.00 or less will be retained by Neurizon and not refunded).

(h) If you are entitled to a refund of all or any of your application monies, the refund will be paid to you, without interest, as soon as is practicable by direct credit to your nominated account (as recorded on the Register). Shareholders are encouraged to update their direct credit details with the Registry.

4.5 Issue Price

(a) The Issue Price per SPP Share is $0.068, being the same offer price as that under the Placement.[5]

(b) The current Share price can be obtained from ASX (www.asx.com.au under the ticker code "NUZ") and is listed in the "Companies&Markets" section of The Australian Financial Review.

(c) You agree to pay the Issue Price per SPP Share for the number of SPP Shares calculated under section 4.6(a) of the Terms and Conditions or, if there is a scale back, the number of SPP Shares calculated under section 4.10 of the Terms and Conditions.

(d) There are risks associated with any stock market investment and we recommend that you obtain your own financial advice in relation to this SPP. In particular, there is a risk that the market price for Neurizon Shares at the time

[5] Represents:

- a 20.9% discount to the closing price of Shares traded on 28 October 2026 being the last trading day prior to the Company entering a two day trading halt to conduct the Placement;
- an 18.9% discount to the 5-day VWAP up to and including 28 October 2026 being the last trading day prior to the Company entering a two day trading halt to conduct the Placement (excluding 28 October 2026 as no sales in Shares were recorded on that day); and
- a 19.3% premium to the closing price of $0.057 as at 12 November 2026.

that SPP Shares are issued will be less than their Issue Price. If this occurs, the value of your investment in SPP Shares will be less than the amount you invested. Accordingly, you should consider price movements of Shares before applying for SPP Shares under the SPP Offer.

4.6 Number of SPP Shares to be issued

(a) If you apply for SPP Shares, you will apply for a certain value, rather than a certain number, of SPP Shares. If your application is accepted, Neurizon will divide the value of your application monies by the Issue Price (as determined under section 4.5(a) of the Terms and Conditions) in order to determine the number of SPP Shares which, subject to scale back, will be issued to you.

(b) If this calculation produces a fractional number, the number of SPP Shares issued will be rounded up to the nearest whole SPP Share.

4.7 Issue of SPP Shares

(a) SPP Shares will be issued on the Issue Date.

(b) SPP Shares will rank equally with existing Shares as at the Issue Date.

(c) Neurizon will apply to ASX for the quotation of SPP Shares.

(d) The Registry will send you a holding statement, confirming the issue of SPP Shares, on or around Tuesday, 15 December 2026.

4.8 Shareholders outside Australia

(a) The laws of some countries prohibit or make impracticable participation in the SPP by certain overseas Shareholders. Neurizon has determined that, in its reasonable opinion, it is not practical for persons with a registered address outside of Australia and New Zealand to participate in the SPP.

(b) This Booklet does not constitute an offer of SPP Shares in any jurisdiction in which it would be unlawful. In particular, this Booklet may not be distributed to any person, and the SPP Shares may not be offered or sold, in any country outside Australia and New Zealand.

(c) The SPP Shares are not being offered or sold to the public within New Zealand other than to Eligible Shareholders with registered addresses in New Zealand to whom the offer of SPP Shares is being made in reliance on the *Financial Markets Conduct (Incidental Offers) Exemption Notice 2021 (New Zealand)*.

(d) This Booklet has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013. This Booklet is not a product disclosure statement under New Zealand law and is not required to, and may not, contain all the information that a product disclosure statement under New Zealand law is required to contain.

(e) Persons in the United States are not eligible to participate in the SPP. Similarly, persons (including Custodians) who hold Shares on behalf of persons who reside outside Australia or New Zealand (including the United States) or are acting for the account or benefit of persons in the United States, are not eligible to participate in the SPP on behalf of those persons.

4.9 Representations, warranties and acknowledgements

By making payment for SPP Shares, you (on your own behalf and on behalf of each person for whose account or on whose behalf you are acting, if applicable):

(a) are deemed to have accepted the SPP Offer and you irrevocably and unconditionally agree to the Terms and Conditions (including, for the avoidance of doubt, the terms and conditions of the Application Form) in full and agree not to do any act or thing that would be contrary to the spirit, intention or purpose of the SPP;

(b) represent and warrant that all details and statements in your application are true and complete and not misleading or deceptive (including by omission);

(c) agree that your application will be irrevocable and unconditional (that is, it cannot be withdrawn);

(d) represent and warrant that you are an Eligible Shareholder and are eligible and lawfully permitted to participate in the SPP and to accept the SPP Offer, and agree to provide (and if applicable direct your nominee or Custodian to provide) any requested substantiation of your eligibility to participate in the SPP and of your holding of Shares on the Record Date;

(e) acknowledge that no interest will be paid on any application monies held pending the issue of SPP Shares or subsequently refunded to you for any reason;

(f) acknowledge that Neurizon and its officers and agents are not liable for any consequences of the exercise or non-exercise of its discretions referred to in these Terms and Conditions;

(g) agree to pay the Issue Price per SPP Share up to the maximum of:

(1) the value you have selected on the Application Form; or

(2) the maximum value of your payment,

(as determined by Neurizon in its absolute discretion);

(h) represent, warrant, acknowledge and agree that:

(1) you are not in the United States and are not acting for the account or benefit of a person in the United States (or, in the event that you are acting for the account or benefit of a person in the United States, you are not participating in the SPP in respect of that person);

(2) at the time the allotment of SPP Shares is made, you will not be in the United States and will not be acting for the account or benefit of a person in the United States (or, in the event that you are acting for the account or benefit of a person in the United States, you are not participating in the SPP in respect of that person);

(3) you understand that the offer and sale of SPP Shares has not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, but rather the issue of the Shares under the SPP Offer will be made in reliance on an exemption from registration contained in Regulation S under the Securities Act for offers and sales made outside of the United States;

(4) you may not and will not offer, sell, pledge, transfer or otherwise dispose of any Shares in the United States or for the account or benefit of any person in the United States unless and unless the Shares have been registered under the Securities Act (which the Eligible Shareholder acknowledges Neurizon has no obligation to do) or are offered, sold, pledged, transferred or otherwise disposed of in a transaction exempt from, or not subject to, the registration requirements of the Securities Act or the laws of any state or other jurisdiction in the United States;

(5) you understand that the SPP Shares are being offered and sold in "offshore transactions" (as defined in Rule 902(h) under Regulation S) in reliance on Regulation S under the Securities Act and are subject to the conditions under Regulation S;

(6) you have not sent, and will not send, this Booklet or any other document relating to the SPP to any person outside of Australia or New Zealand (including without limitation, to any person in the United States);

(7) you are not in the business of distributing securities;

(8) if in the future you decide to sell or otherwise transfer the SPP Shares, you will only do so in the regular way for transactions on ASX where neither you nor any person acting on your behalf knows, or has reason to know, that the sale has been pre-arranged with, or that the purchaser is, a person outside of Australia or New Zealand (including, without limitation, to any person in the United States); and

(9) if you are acting as a nominee or Custodian, each beneficial holder on whose behalf you are participating is resident in Australia or New Zealand (and is not in the United States);

(i) if you are applying for SPP Shares on your own behalf (and not as a Custodian) represent, warrant, acknowledge and agree that:

(1) you are not applying for SPP Shares with an aggregate application price of more than $30,000 under the SPP Offer (including any SPP Shares which a Custodian has applied to purchase on your behalf under the SPP Offer); and

(2) the aggregate application price for the following does not exceed $30,000:

(A) the SPP Shares the subject of the application;

(B) any other Shares issued to you under the SPP Offer or any similar arrangement in the 12 months before the application;

(C) any other SPP Shares which you have instructed a Custodian to acquire on your behalf under the SPP Offer; and

(D) any other Shares issued to a Custodian in the 12 months before the application as a result of an instruction given by you to the Custodian to apply for Shares on your behalf under an arrangement similar to the SPP,

even though you may have received more than one offer under the SPP or received offers in more than one capacity under the SPP;

(j) if you are a Custodian and are applying for SPP Shares in such capacity, represent, warrant, acknowledge and agree that:

(1) you are a Custodian;

(2) you held Shares on behalf of the Eligible Beneficiary as at the Record Date who has instructed you to apply for SPP Shares on their behalf under the SPP Offer and that the Eligible Beneficiary was provided with a copy of this Booklet before giving such instruction;

(3) you are not applying for SPP Shares on behalf of any Eligible Beneficiary with an aggregate application price of more than $30,000 under the SPP Offer; and

(4) the information in the Custodian Certificate submitted with your Application Form is true, correct and not misleading or deceptive (including by omission);

(k) accept the risk associated with any refund that may be despatched to you;

(l) agree to be bound by the constitution of Neurizon;

(m) represent and warrant that you are in compliance with all relevant laws and regulations (including, without limitation, section 1043A of the Corporations Act (insider trading) and laws and regulations designed to restrict terrorism financing and/or money laundering);

(n) represent that you are not a "designated person" or "designated entity" (or other like term) for the purpose of any domestic or international law or regulation implementing United Nations sanctions;

(o) acknowledge that Neurizon may vary the timetable set out in this Booklet (including any specific dates in that timetable) at its discretion by lodging a revised timetable with ASX;

(p) acknowledge that the market price of Shares may rise or fall between the date of the SPP Offer and the Issue Date and that the Issue Price you pay for SPP Shares may exceed the market price of Shares on the Issue Date;

(q) acknowledge that there are risks associated with acquiring and holding Shares, including those described in Neurizon's ASX announcement dated 2 November 2026;

(r) acknowledge that none of Neurizon or its subsidiaries or their respective directors, officers, employees, advisers or agents has provided you with any financial product or investment advice or taxation advice in relation to the SPP, or has any obligation to provide such advice, and that this Booklet has been prepared without taking into account the objectives, financial situation, tax position or needs of individuals;

(s) authorise Neurizon, and its officers and agents, to do anything on your behalf necessary for SPP Shares to be issued to you in accordance with these Terms and Conditions and to register you as the holder(s) of SPP Shares issued to you;

(t) acknowledge that, by making payment of application monies, you will be taken to have made all representations, warranties and undertakings set out in the Application Form as if you had validly signed and submitted an Application Form;

(u) acknowledge that Neurizon may at any time and in its absolute discretion determine that your application is valid, in accordance with the Terms and Conditions;

(v) authorise Neurizon, and its officers and agents, to correct any minor or easily rectified error(s) in, or omission(s) from, your application;

(w) acknowledge that Neurizon may, in its absolute discretion, make reductions in the issue of SPP Shares under a scale back;

(x) acknowledge that the new Options will be offered under a prospectus and not under this Booklet, that the issue of new Options is subject to Shareholder approval at the General Meeting and satisfaction of the quotation condition and that, if that approval is not obtained and/or the quotation condition is not satisfied, no new Options will be issued to you and your application for SPP Shares will not be affected; and

(y) declare that you are at least 18 years of age and have full legal capacity and power to perform all your rights and obligations in respect of the SPP Offer.

4.10 Scale back

(a) Subject to section 4.10(b) of the Terms and Conditions below, Neurizon has determined that it will target to raise through the SPP $2 million and accordingly if demand exceeds such amount, Neurizon will have the discretion to undertake a scale back of applications for SPP Shares (in whole or in part) at the absolute discretion of Neurizon to the extent, and in the manner, it sees fit.

(b) Neurizon may (in its absolute discretion) in a situation where total demand exceeds $2 million, decide to increase the amount to be raised under the SPP to reduce scale back.

(c) If there is a scale back, you may receive less than the parcel of SPP Shares for which you have applied.

(d) If a scale back produces a fractional number of SPP Shares when applied to your parcel, the number of SPP Shares you will be issued will be rounded up to the nearest whole number of SPP Shares.

(e) If there is a scale back, the difference between the application monies received *from* you, and the number of SPP Shares allocated to you multiplied by the Issue Price will be refunded to you (without interest) (except that any excess amount of $5.00 or less will be retained by Neurizon and not refunded).

(f) When deciding on the amount to apply for, please consider the impact of the potential scale back as it may impact the number of SPP Shares you receive. Your allocation may be scaled back and you will receive a refund for the balance of your application (without interest) (except that any excess amount of $5.00 or less will be retained by Neurizon and not refunded).

4.11 Dispute resolution

(a) Neurizon may settle, in any manner it deems appropriate, any difficulties, anomalies, or disputes which may arise in connection with, or by reason of, the operation of the SPP whether generally or in relation to any participant or any application for SPP Shares, and its decision shall be conclusive and binding on all participants and other persons to whom the determination relates.

(b) The powers of Neurizon under these Terms and Conditions may be exercised by the Directors or any delegate or representative of the Directors.

4.12 Variation and termination

(a) Neurizon reserves the right at any time to:

(1) amend or vary these Terms and Conditions;

(2) waive strict compliance with any provision of these Terms and Conditions;

(3) withdraw the SPP Offer or suspend or terminate the SPP;

(4) vary the timetable for the SPP, including the Closing Date; and

(5) not accept an application, not issue SPP Shares, or issue SPP Shares to a value less than that applied for under the SPP Offer by an Eligible Shareholder (including a Custodian applying on behalf of its Eligible Beneficiaries).

(b) Any such amendment, variation, waiver, suspension, withdrawal, non-acceptance or termination will be binding on all Eligible Shareholders even where Neurizon does not notify you of that event.

(c) In the event that the SPP is withdrawn or terminated, all application monies will be refunded (without interest).

4.13 Privacy policy

(a) Chapter 2C of the Corporations Act requires information about a shareholder (including your name, address and details of the securities you hold) to be included in the public register of the entity in which you hold securities. This information must continue to be included in the public register (for the period specified in Chapter 2C of the Corporations Act) if you cease to be a Shareholder.

(b) Neurizon and the Registry may collect personal information to process your application, implement the SPP and administer your holding of Shares. The personal information contained in the Register is also used to facilitate payments and corporate communications (including financial results), annual reports and other information to be communicated to Shareholders, and to ensure compliance with legal and regulatory requirements (as applicable).

(c) Your personal information may be disclosed to joint investors, the Registry, securities brokers, third party service providers (including print and mail service providers, technology providers and professional advisers), related entities of Neurizon and its agents and contractors, and ASX and other regulatory authorities, and in any case, where disclosure is required or allowed by law (which may include disclosures to government or regulatory bodies (as applicable) or where you have consented to the disclosure). In some cases, the types of organisations referred to above to whom your personal information may be disclosed may be located overseas.

(d) The Registry's privacy policy is available at https://www.automicgroup.com.au/privacy-policy/.

4.14 ASIC Corporations Instrument compliance

A Shareholder will be ineligible to participate in the SPP if their participation would be in breach of *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547*.

4.15 Underwriting

The SPP is not underwritten.

4.16 Governing law

(a) These Terms and Conditions are governed by the laws in force in Victoria. Any dispute arising out of, or in connection with, these Terms and Conditions, or the SPP Offer, will be determined by the courts of Victoria. By accepting the SPP Offer, you agree to submit to the exclusive jurisdiction of the courts in Victoria. Other terms and conditions, and rights and obligations in respect of Shares, are contained in the constitution of Neurizon.

(b) These Terms and Conditions prevail to the extent of any inconsistency with the Application Form.

5 Glossary

The following definitions apply throughout this Booklet unless the context requires otherwise.

Term	Meaning
$	Australian dollars.
Application Form	your personalised application form.
ASIC	Australian Securities and Investments Commission.
ASX	ASX Limited (ACN 008 624 691), or the market operated by it, as the context requires.
Booklet	this document which sets out, among other things, the SPP Offer.
Closing Date	5.00pm (Melbourne time) on Friday, 4 December 2026 (or such other date as Neurizon determines, in its absolute discretion).
Corporations Act	the *Corporations Act 2001* (Cth).
Custodian	a custodian as defined in section 4 of *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547.*
Custodian Certificate	a certificate complying with section 8(3) of *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547*.
Directors	the directors of Neurizon.
EFT	electronic funds transfer.
Eligible Beneficiary	a person: (a) on whose behalf a Custodian holds Shares as at the Record Date; (b) who has a registered address in either Australia or New Zealand; and

Term	Meaning
	(c) who is not in the United States and is not acting for the account or benefit of a person in the United States or, in the event that such person is acting for the account or benefit of a person in the United States, such person is not participating in the SPP in respect of that person.
Eligible Shareholder	a person who was a registered holder of Shares on the Record Date with a registered address in either Australia or New Zealand at that time as shown on the Register provided that such holder is not in the United States and is not acting for the account or benefit of a person in the United States or, in the event that such holder is acting for the account or benefit of a person in the United States, such holder is not participating in the SPP in respect of that person.
General Meeting	has the meaning given in section 1 of this Booklet.
Issue Date	Friday, 11 December 2026 (or such other date as Neurizon determines, in its absolute discretion).
Issue Price	$0.068 per SPP Share.
Listing Rules	the official listing rules of ASX that govern the admission, quotation and removal of securities from the ASX official list.
Neurizon or **Company**	Neurizon Therapeutics Limited (ABN 35 094 006 023).
Offer Period	the period commencing on the Opening Date and ending on the Closing Date.
Opening Date	9.00am (Melbourne time) Monday, 16 November 2026.
Option	an option which, subject to its terms and payment of the exercise price, may be exercised into a Share.
Placement	the placement of Shares to sophisticated and professional investors, announced to ASX on Monday, 2 November 2026.
Record Date	7.00pm (Melbourne time) on Friday, 30 October 2026.

Term	Meaning
Register	the register of Shareholders.
Registry	Automic Pty Ltd (ABN 27 152 260 814).
Securities Act	the U.S. Securities Act of 1933, as amended.
Share	a fully paid ordinary share in Neurizon.
Shareholder	a holder of one or more Shares.
SPP	the Share Purchase Plan under which Eligible Shareholders may apply for SPP Shares on the terms set out in this Booklet.
SPP Share	has the meaning given in section 1 of this Booklet.
SPP Offer	the offer in section 4.1(a) of the Terms and Conditions.
Terms and Conditions	the terms and conditions of the SPP set out in section 4 of this Booklet, together with the other provisions of this Booklet and the Application Form which are incorporated into those terms and conditions as set out in that section.
U.S.	United States.
VWAP	volume weighted average price.

Neurizon

Neurizon Therapeutics Limited | ACN 094 006 023

All Registry Communication to:

AUTOMIC GROUP

GPO Box 5193, Sydney NSW 2001
1300 288 664 (within Australia)
+61 2 9698 5414 (international)
corporate.actions@automicgroup.com.au
www.automicgroup.com.au

[EntityRegistrationDetailsLine1Envelope]
[EntityRegistrationDetailsLine2Envelope]
[EntityRegistrationDetailsLine3Envelope]
[EntityRegistrationDetailsLine4Envelope]
[EntityRegistrationDetailsLine5Envelope]
[EntityRegistrationDetailsLine6Envelope]

Holder Number:
[HolderNumberMasked]

Record Date:
7.00pm (Melbourne time) on 30 October 2026

SHARE PURCHASE PLAN AND OPTIONS APPLICATION FORM

OFFER CLOSES 5.00PM (MELBOURNE TIME) 4 DECEMBER 2026 (WHICH MAY CHANGE WITHOUT NOTICE)

This SPP Offer entitles each Eligible Shareholder in Neurizon Therapeutics Limited (**Neurizon** or the **Company**) to subscribe through the Company's Share Purchase Plan (**SPP**) for a maximum of $30,000 worth of new Shares in Neurizon (**SPP Shares**). The SPP aims to raise $2 million. If total demand exceeds $2 million, Neurizon may decide to increase the amount to be raised under the SPP to reduce or eliminate the need for scale back. The SPP is open to persons who were registered holders of Shares in Neurizon at 7.00pm (Melbourne time) on 30 October 2026 with a registered address in either Australia or New Zealand at that time as shown on the Register (and who meet certain other eligibility criteria) (**Eligible Shareholders**). The issue price is $0.068 per SPP Share (**Issue Price**).

Participants under the SPP will also be entitled to be made a separate offer by the Company, subject to Shareholder approval at the General Meeting, to apply to receive (for no consideration) 1 new Option for every 1 SPP Share subscribed for under the SPP (rounded down to the nearest whole number). The new Options will be offered to eligible participants via a prospectus lodged with ASIC and released to ASX on or around Monday, 16 November 2026 and available at https://portal.automic.com.au/investor/home (**Prospectus**). By applying to participate in the SPP, you will also have applied for the same number of new Options as SPP Shares subscribed for under the SPP Offer. Eligible participants should carefully read the Prospectus in full before applying for new Options. This Application Form also constitutes the "SPP Options Application Form" for the purposes of the Prospectus.

1 SUBSCRIPTION

Eligible Shareholders may subscribe for any one of the following parcels (subject to a maximum band or any scale back) described below by paying the applicable application amount in accordance with the payment instructions in Section 2 of this Application Form:

	Application Amount	Number of SPP Shares
Offer A	**$1,000 (minimum)**	**14,706**
Offer B	**$2,500**	**36,765**
Offer C	**$5,000**	**73,530**
Offer D	**$7,500**	**110,295**
Offer E	**$10,000**	**147,059**

	Application Amount	Number of SPP Shares
Offer F	**$12,500**	**183,824**
Offer G	**$15,000**	**220,589**
Offer H	**$20,000**	**294,118**
Offer I	**$25,000**	**367,648**
Offer J	**$30,000 (maximum)**	**441,177**

2 PAYMENT - YOU CAN PAY BY BPAY® OR ELECTRONIC FUNDS TRANSFER (EFT)

Payments must be made in Australian dollars via BPAY or EFT. You do not need to return this Application Form.

Option A – BPAY

Biller Code: [BPayBillerCd]

Ref: [BPayCRN]

Mobile & Internet Banking – BPAY®
Make this payment from your cheque or savings account.

Note: Please ensure you use the BPAY details stated above as they are unique for each offer. Your BPAY reference number or unique entitlement reference number will process your payment for your application for SPP Shares electronically.

Option B – Electronic Funds Transfer (EFT)

Funds are to be deposited in AUD currency directly to following bank account:

Account name: Automic Pty Ltd
Account BSB: [CreditAccountBsb]
Account number: [CreditAccountNumber]
Swift Code: WPACAU2S

Your unique entitlement reference number:
[HolderId]-[CorporateActionID]-[CompanyASXCode]

IMPORTANT: You must quote your **unique entitlement reference number** as your payment reference/description when processing your EFT payment. Failure to do so may result in your funds not being allocated to your application and SPP Shares subsequently not issued.

3 ELECT TO RECEIVE COMMUNICATIONS ELECTRONICALLY

We encourage you to elect to receive Shareholder communications electronically to:

- Help the Company reduce its printing and mailing costs
- Receive investor communications faster and more securely
- Help the environment through the need for less paper.

SCAN THE QR CODE TO VISIT
HTTPS://PORTAL.AUTOMIC.COM.AU/INVESTOR/HOME
AND UPDATE YOUR COMMUNICATION PREFERENCE

SAMPLE

® Registered to BPAY Pty Ltd ABN 69 079 137 518

INSTRUCTIONS FOR COMPLETION OF THIS APPLICATION FORM

The right to participate in the SPP is optional and is offered exclusively to Eligible Shareholders (including Custodians).

If the Company rejects or scales-back an application or purported applications, the Company will return to the Shareholder the relevant application amount (without interest) (except that any excess amount of $5.00 or less will be retained by Neurizon and not refunded).

HOW TO APPLY FOR SHARES UNDER THE SPP

1 Subscription

As an Eligible Shareholder, you can apply for up to a maximum of $30,000 worth of SPP Shares. Eligible Shareholders can select one of the parcels prescribed overleaf.
In order to comply with ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547, the maximum value of SPP Shares each Eligible Shareholder (irrespective of the size of their shareholding) may apply for under this SPP Offer is $30,000 (including through joint holding(s), multiple share accounts or any holding in which they have a beneficial interest/s). This limit will apply even if you receive more than one offer from the Company (for example, because you are a joint holder of Shares or because you hold more than one shareholding under separate share accounts).
If the Company receives an amount that does not equal one of the amounts specified overleaf the Company may accept the payment at their discretion and refund any excess application amount (without interest) to the Eligible Shareholder. If the Company receives a subscription of over $30,000 worth of SPP Shares by an Eligible Shareholder through multiple applications or joint holdings, the Company may refund any excess application amount (without interest) to the Eligible Shareholder.
Any application made under the SPP Offer is not guaranteed to result in the Eligible Shareholder receiving any SPP Shares that have been applied for. Applications may be scaled back at the absolute discretion of the Company to the extent, and in the matter, it sees fit.

2 Payment

By making a payment via BPAY or EFT, you agree that it is your responsibility to ensure that funds are submitted correctly and received by Automic Share Registry by the closing date and time. Payment must be received by the Registry by the Closing Date by being 5.00pm (Melbourne time) on Friday, 4 December 2026 (or such other date as Neurizon determines, in its absolute discretion). It is your responsibility to ensure your CRN or unique payment reference is quoted, as per the instructions in Section 2. If you fail to quote your CRN or unique payment reference correctly, Automic may be unable to allocate or refund your payment. If you need assistance, please contact Automic.

Payment by BPAY®: You can make a payment via BPAY® if you are the holder of an account with an Australian financial institution that supports BPAY® transactions. To BPAY® this payment via internet or telephone banking use your reference number on this Application Form. Multiple acceptances must be paid separately.

Payment by EFT: You can make a payment via Electronic Funds Transfer "EFT". Multiple acceptances must be paid separately. Please use your unique reference on this Application Form. This will ensure your payment is processed correctly to your application electronically.
Applicants should be aware of Automic's financial institution's cut off-time, their own financial institution's cut-off time and associated fees with processing a funds transfer.

It is the applicant's responsibility to ensure funds are submitted correctly by the Closing Date, including taking into account any delay that may occur as a result of payments being made after 5pm (Sydney time) and/or on a day that is not a business day (payment must be made to be processed overnight). You do not need to return this Application Form. Your reference number will process your payment to your application electronically and you will be deemed to have applied for such SPP Shares for which you have paid.

3 Elect to receive communications electronically

As a valued Shareholder, the Company encourages Shareholders to elect to receive their Shareholder communications electronically. This will ensure you receive all future important Shareholder communications in a faster and more secure way and reduce the environmental footprint of printing and mailing.

IMPORTANT INFORMATION

1. This is an important document which requires your immediate attention. If you are in any doubt as to how to deal with this Application Form, please consult a professional adviser.
2. If you do not wish to purchase SPP Shares under the SPP, there is no need to take action.
3. Please ensure you have read and understood the terms and conditions of the SPP contained in the SPP booklet available at https://portal.automic.com.au/investor/home (**Booklet**) and this section entitled "Important Information" before making payment by BPAY® or EFT. Capitalised terms not otherwise defined in this Application Form are defined in the Booklet.
4. The offer for SPP Shares under the SPP is non-renounceable. Applications can only be accepted in the name printed on this Application Form.
5. If you are a custodian, trustee or nominee within the meaning of "Custodian" as defined in ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547, you must complete and submit an additional certificate that contains further certifications and details (**Custodian Certificate**) that must be provided before your application will be received. The Custodian Certificate can be obtained by contacting the Registry on the telephone number set out below. Applications received by Custodians that are not accompanied by the Custodian Certificate will be rejected. A completed Custodian Certificate must be emailed to: custodialcertificates@automicgroup.com.au**,** failure to do so will result in the application being rejected.
6. For applicants that are not required to complete the Custodian Certificate, by making payment you certify and represent to Neurizon that:
   - you are not applying for SPP Shares with an aggregate application price of more than 30,000 under the SPP Offer (including by instructing a Custodian to acquire SPP Shares on your behalf under the SPP Offer); and
   - the aggregate application price does not exceed $30,000 in relation to:
     a. the SPP Shares that are the subject of this application;
     b. any other Shares issued to you under the SPP Offer or any similar arrangement in the 12 months before the application;
     c. any other SPP Shares which you have instructed a Custodian to acquire on your behalf under the SPP Offer; and
     d. any other Shares issued to a Custodian in the 12 months before this application as a result of an instruction given by you to the Custodian to apply for Shares on your behalf under an arrangement similar to the SPP,

   even though you may have received more than one offer under the SPP or received offers in more than one capacity under the SPP.
7. The maximum subscription limitation of $30,000 will apply even if you have received more than one Application Form (whether in respect of a joint holding or because you have more than one shareholding under separate share accounts).
8. You are not guaranteed to receive any SPP Shares that you have applied for and the Company may, in its absolute and sole discretion:
   a. scale back any applications made; and
   b. reject your application, without limit.
9. By making payment of application monies, you certify that:
   - you wish to apply for SPP Shares under the SPP as indicated on this Application Form and acknowledge that your application is irrevocable and unconditional;
   - you received a copy of the Booklet and you have read and understood the terms and conditions of the SPP;
   - you agree to be bound by the Constitution of the Company and the terms and conditions in the Booklet;
   - you agree to accept any lesser number of SPP Shares than the number of SPP Shares applied for; and
   - you are not in the United States and are not acting for the account or benefit of a person in the United States and have not sent any offering materials relating to the SPP offer to any person in the United States.

If you require further information about the SPP Offer, please contact Automic line on 1300 288 664 (for callers within Australia) or +61 2 9698 5414 (for callers outside Australia) between 8.30am and 7.00pm (Melbourne time), Monday to Friday (excluding public holidays) or email corporate.actions@automicgroup.com.au during the Offer Period.

SAMPLE

16 November 2026

Dear Shareholder

IMPORTANT NOTICE TO ELIGIBLE SHAREHOLDERS - OPPORTUNITY TO PARTICIPATE IN A SHARE PURCHASE PLAN AND OPTIONS OFFER

Neurizon Therapeutics Limited **(Neurizon** or the **Company)** is pleased to offer the opportunity to participate in a Share Purchase Plan **(SPP)** to persons who were registered holders of Shares in Neurizon at 7.00pm (Melbourne time) on Friday, 30 October 2026 **(Record Date),** with a registered address in either Australia or New Zealand (and who meet certain other eligibility criteria) **(Eligible Shareholders)** to acquire up to $30,000 worth of new Shares in Neurizon **(SPP Shares)** at an Issue Price of $0.068 per SPP Share. Participation in the SPP Offer is voluntary and open to all Eligible Shareholders.

The Booklet in relation to the SPP Offer has been given to ASX and is available to view on the ASX website and Neurizon website at https://investorhub.neurizon.com/announcements. Further details regarding the SPP Offer have also been announced to the ASX and are available on ASX's website. Shareholders should carefully read the Booklet in full prior to making an application under the SPP. Capitalised terms not otherwise defined in this letter are defined in the Booklet.

Participants under the SPP will also be entitled to be made a separate offer by the Company, subject to Shareholder approval at the General Meeting, to apply to receive (for no consideration) 1 new Option for every 1 SPP Share subscribed for under the SPP (rounded down to the nearest whole number). Subject to satisfying spread requirements set out in Listing Rule 2.5, condition 6, the new Options are intended to be quoted on the ASX and the issue of new Options is subject to such quotation. The new Options will be offered to eligible participants via a prospectus lodged with ASIC and released to ASX on or around Monday, 16 November 2026 (**Prospectus**). By applying to participate in the SPP, you will also have applied for the same number of new Options as SPP Shares subscribed for under the SPP Offer. Eligible participants should carefully read the Prospectus in full before applying for new Options.

Neurizon will not be printing/ dispatching hard copies of the Booklet, Prospectus or application forms. Instead, an electronic copy of the Booklet, Prospectus and your application form is available and accessible by you (using your Securityholder Reference Number (SRN) or Holder Identification Number (HIN) from your latest Holding Statement, and your postcode) at the following link: https://portal.automic.com.au/investor/home.

Your application under the SPP Offer must be made by making payment in accordance with the personalised payment instructions.

1. **ONLINE** – The Booklet, Prospectus and personalized Application Form can be accessed via: https://portal.automic.com.au/investor/home

2. **PAPER** - Request a paper copy of the Booklet and the personalised Application Form by contacting the Company's Registry, Automic on 1300 288 664 (for callers within Australia) or +61 2 9698 5414 (for callers outside Australia) between 8.30am and 7.00pm (Melbourne time), Monday to Friday (excluding public holidays) or email corporate.actions@automicgroup.com.au during the Offer Period.

SAMPLE

To download your Application Form you have the following 3 choices:

I already have an online account with the Automic Share registry	I don't have an online account with Automic and wish to register for one	I don't have an online account with Automic – but wish to use Automic for this Offer only
https://portal.automic.com.au/investor/home Select: "Existing Users Sign In". Once you have successfully signed in, click on "Documents and Statements". Download the Booklet, Prospectus and Application Form. Submit your payment using the payment details provided on your personalised Application Form. **Do not return your Application Form.**	https://singleholding.automic.com.au/signup Select **Neurizon Therapeutics Limited** from the dropdown list in the ISSUER field. Enter your holder number SRN / HIN (from your latest Holding Statement). Enter a single identifying word from your holder name. Enter your Postcode (Australia) or Country of Residence (Outside Australia). Tick box "I am not a robot", then click Next and complete the prompts. Once you have successfully signed in, click on "Documents and Statements". Download the Booklet, Prospectus and Application Form. Submit your payment using the payment details provided on your personalised Application Form. **Do not return your Application Form.**	https://singleholding.automic.com.au/login Select **Neurizon Therapeutics Limited** from the dropdown list in the ISSUER field. Enter your holder number SRN / HIN (from your latest Holding Statement). Enter a single identifying word from your holder name. Enter your Postcode (Australia) or Country of Residence (Outside Australia). Tick box "I am not a robot", then click Next and complete the prompts. Once you have successfully signed in, click on "Documents and Statements". Download the Booklet, Prospectus and Application Form. Submit your payment using the payment details provided on your personalised Application Form. **Do not return your Application Form.**

If you are unable to access https://portal.automic.com.au/investor/home online, you can obtain a copy of the Booklet, Prospectus and your Application Form by contacting the Company's Share Registry, Automic on 1300 288 664 (for callers within Australia) or: +61 2 9698 5414 (for callers outside Australia) between 8.30am and 7.00pm (Melbourne time), Monday to Friday (excluding public holidays) or email corporate.actions@automicgroup.com.au during the Offer Period. To accept the SPP Offer using these paper copy documents, you will still need to make payment via BPAY or EFT.

SAMPLE

The SPP Offer closes at 5.00pm (Melbourne time) on Friday, 4 December 2026.

Event	Date
Record Date (the date that eligibility to participate in the SPP was determined)	7.00pm (Melbourne time), Friday, 30 October 2026
Opening Date for applications	9.00am (Melbourne time), Monday, 16 November 2026
Closing Date for applications	5.00pm (Melbourne time), Friday, 4 December 2026
Results of SPP announced	Friday, 11 December 2026
Issue of SPP Shares	Friday, 11 December 2026
SPP Shares commence trading on ASX	Monday, 14 December 2026
Despatch of holding statements	Tuesday, 15 December 2026
General Meeting	Thursday, 17 December 2026

These dates are indicative only and subject to change. Neurizon reserves the right to change any date including to extend the closing date of the SPP Offer, to close the SPP Offer early, to accept late acceptances either generally or in particular cases, or to withdraw or reduce the size of the SPP Offer without notice. Any extension of the closing date will have a consequential effect on the issue date of new shares.

For further information about how to participate in the SPP Offer, please contact Automic.

Email: corporate.actions@automicgroup.com.au

Phone: 1300 288 664 (for callers within Australia) or +61 2 9698 5414 (for callers outside Australia) between 8.30 am and 7.00pm (Melbourne time) Monday to Friday (excluding public holidays) during the Offer Period.

Sergio Duchini
Chair

Neurizon Therapeutics Limited

SAMPLE

Elect to receive communications electronically

You have received this letter by post, as you have not provided your email address or elected to receive all communications electronically. We encourage you to elect to receive shareholder communications electronically, to update your communication preference scan the QR code to visit **https://portal.automic.com.au/investor/home**.